a9e8922f-fd6c-412d-85f5-40f5ea9b5455
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.380
- HEDGEHOG_SIGNALING+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
- G2M_CHECKPOINT+0.190
- UV_RESPONSE_DN+0.160
- MITOTIC_SPINDLE+0.140
- APICAL_JUNCTION+0.100
- E2F_TARGETS+0.090
- MYC_TARGETS_V2+0.060
- MYOGENESIS+0.060
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.600
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.490
- ADIPOGENESIS-0.460
- ALLOGRAFT_REJECTION-0.460
- FATTY_ACID_METABOLISM-0.450
- COMPLEMENT-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- PEROXISOME-0.380
- INFLAMMATORY_RESPONSE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013547 | — | cohortMD1 | 0.924 |
| 2 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.914 |
| 3 | TCGA-90-A4ED-01A-31R-A24Z-07 | — | cohortMD1 | 0.889 |
| 4 | TCGA-58-8388-01A-11R-2326-07 | — | cohortSQ1 | 0.881 |
| 5 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.871 |
| 6 | TCGA-A1-A0SB-01A-11R-A144-07 | — | A | 0.859 |
| 7 | BS_4E1G7E3G | ATRT | — | 0.856 |
| 8 | C3N-02435 | — | cohortSQ1 | 0.855 |
| 9 | GSM5359422 | — | — | 0.850 |
| 10 | SRR8613798 | — | D | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.010 | Remibrutinib | — uncovered |